Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Commercial Insight Top 20 cancer therapy brands forecast | Oct 2010 | £9,615 | 100% |
| Top 20 Cancer Therapy Brands in Australia Forecast | Mar 2010 | £3,605 | 99% |
| Commercial Insight: Antihormonal Cancer Therapies | Jul 2009 | £9,615 | 92% |
| Cancer Supportive Care Products Market to 2016 Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars |
Apr 2011 | £2,215 | 85% |
| Stakeholder Insight: Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge |
Oct 2006 | £8,365 | 85% |
| Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
Feb 2007 | £1,820 | 85% |
| Lung Cancer Therapeutics Market Outlook and Pipeline Analysis | Nov 2009 | £945 | 85% |
| Stakeholder Insight: Gastric Cancer | Sep 2010 | £9,615 | 85% |
| Oncology Adjuvants Technologies and Global Markets |
Aug 2010 | £3,065 | 85% |
| Pain Management Therapeutics Market to 2017 Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta |
Nov 2011 | £2,215 | 84% |
| Minimally Invasive BPH and Prostate Cancer Treatment Devices Markets Worldwide | Dec 2010 | £1,580 | 81% |
| China Dermatosis Drug Market Report The Chinese Hospital Cancer Drug Utilization |
Feb 2009 | £5,060 | 81% |
| Opioids Market to 2017 Steady Uptake of Oxycontin and High Incidence of Diseases Such as Cancer and Arthritis to Drive The Market |
Jun 2011 | £2,215 | 81% |
| Currently Druggable in Colorectal Cancer A Drug Target Competitive Analysis |
Dec 2008 | £1,620 | 81% |
| The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 Increasing Generic Competition Creates Challenges |
Mar 2010 | £2,215 | 80% |
| Radiation Therapy Equipment | Oct 2010 | £2,845 | 80% |
| The Future of Oncology Therapeutics Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis |
Dec 2009 | £2,215 | 80% |
| Top 10 Healthcare Trends in 2011 | Mar 2011 | £2,215 | 80% |
| Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020 | Nov 2010 | £1,895 | 79% |
| U.S. and Worldwide Monoclonal Antibody Medicine Current Status and Future Trends |
Aug 2008 | £945 | 79% |
| Bladder Cancer Pipeline Assessment and Market Forecasts to 2017 |
Dec 2010 | £1,265 | 79% |
| Global Protein Therapeutics Market Analysis | Jul 2011 | £1,140 | 79% |
| Drug Brand Perceptions: Breast Cancer a social media analysis |
Jul 2010 | £295 | 79% |
| Evolution in the Pain Therapy Drugs Market Nociceptive and Neuropathic Drug Development |
Jan 2012 | £1,295 | 79% |
| The Global Cancer Vaccine Market Pipeline Analysis and Future Market Impact |
Feb 2011 | £1,740 | 78% |
| Cancer Generics Market Analysis | Sep 2011 | £630 | 78% |
| Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The Challenge Of Turning Technology Into Therapy |
Jul 2007 | £1,999 | 77% |
| Mylan Inc.: PharmaVitae Profile | Jan 2010 | £3,605 | 76% |
| Pharmacogenomics: New Technologies In the Development of Personalized Therapies |
Sep 2005 | £2,760 | 76% |
| Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects | Aug 2008 | £1,495 | 75% |
